A transformative shift in the treatment landscape for type 2 diabetes and obesity is unfolding, as the widely used class of glucagon-like peptide-1 (GLP-1) therapies, previously known primarily as weekly injectable formulations, is increasingly being adapted into accessible daily oral pill variants. This breakthrough carries particular significance for low- and middle-income nations across the Global South, where soaring diabetes prevalence, strained healthcare infrastructure, cold chain storage limitations, and high costs of injectable GLP-1 products have long created steep barriers to life-saving care.